Double Blind, Placebo-controlled Study of Raloxifene for Negative Symptoms of Schizophrenia in Postmenopausal Women
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Primary objective: To assess the efficacy of adding raloxifene as an adjunct to antipsychotic
treatment to improve negative symptoms of schizophrenia in postmenopausal women.
This is a double-blind, randomized, placebo-controlled study of raloxifene as adjuvant
treatment to antipsychotic treatment. Treatment period of 12 weeks.
The primary result obtained is that women treated with 60 mg of raloxifene compared to those
treated with a placebo show greater improvement in psychotic symptoms. The investigators also
found improved response in some aspects of social functioning and neuropsychological
functioning.